

# Contents

---

Contributors vii

- 1 Inhibition of Vascular Endothelial Growth Factor Receptor Signaling in Angiogenic Tumor Vasculature 1**  
Marina V. Backer, Carl V. Hamby, and Joseph M. Backer
  - I. Introduction 2
  - II. VEGF/VEGFR Signaling Pathway as a Target of Antiangiogenic Therapy 3
  - III. Strategies to Inhibit the VEGF/VEGFR Signaling 4
  - IV. Using VEGFR-2 for Targeted Delivery of Powerful Toxic Agents 8
  - V. Summary 22
  - References 22
  
- 2 Adeno-Associated Viral Vectors and Their Redirection to Cell-Type Specific Receptors 29**  
Stefan Michelfelder and Martin Trepel
  - I. Introduction 30
  - II. Capsid Modifications of AAV to Target Cellular Receptors 38
  - III. Selecting Novel AAV Vectors from Combinatorial Libraries 41
  - IV. Perspectives 50
  - References 51
  
- 3 Tissue-Specific Targeting Based on Markers Expressed Outside Endothelial Cells 61**  
Mikhail G. Kolonin
  - I. Introduction 62
  - II. Nonendothelial Tissue-Specific Targets of Systemically Administered Agents 69
  - III. Concluding Remarks and Future Directions 90

|                |    |
|----------------|----|
| Acknowledgment | 92 |
| References     | 92 |

#### **4 Ligand-directed Cancer Gene Therapy to Angiogenic Vasculature 103**

Wouter H. P. Driessen, Michael G. Ozawa,  
Wadih Arap, and Renata Pasqualini

|                                                  |     |
|--------------------------------------------------|-----|
| I. Introduction                                  | 104 |
| II. Therapeutic Concepts in Cancer Gene Therapy  | 105 |
| III. Vectors for Ligand-directed Gene Delivery   | 109 |
| IV. Ligands for Targeting Angiogenic Vasculature | 112 |
| V. Conclusion                                    | 115 |
| References                                       | 115 |

Index 123

Color Plate Section at the end of the Book